An Efficient Drug Compound Analysis Using Spectral Deep Feature Classification Based Compound Analyse Model for Drug Recommendation - 25/02/22

Doi : 10.1016/j.neuri.2022.100059 
S. Dinakaran a, P. Anitha b
a Anna University, Chennai, Tamilnadu, India 
b Department of MCA, KSR College of Engineering, Tiruchengode, Namakkal, Tamilnadu, India 

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

En prensa. Manuscrito Aceptado. Disponible en línea desde el Friday 25 February 2022
This article has been published in an issue click here to access

Abstract

Owing to the day-to-day developments in the modern environment and food nature, humans are affected by various types of diseases like Covid-19. The disease recovering stage needs prolonged treatment, which demands various drugs based on the patient's health condition. The main problem is the drug recommendation and the drug compound molecules that are not relational to curing diseases that lead to side effects. So, knowledge analyzing factors based on the relational feature selection approach are needed to make the best recommendation. To improve the performance of drug recommendations based on a machine learning approach, a Spectral Deep Feature Classification based Compound Analyse Model (SDFC-CAM) is intended for analyzing the success rate of drug recommendations. The features are processed with Mutual Spectral Scaling Feature Selection (MS2FS) filter and inputs are given to Inter-Segment Sigmoid Activation Adaptive Recurrent Neural Network (InS2ARNN) to make recommended classes. The system initially pre-processes all the patients' nature and their recommended drug molecule compounds as a collective dataset. The feature selection is carried out to generate relational patterns using the distance vector features correlated to mutual molecules weights. The features are selected from the success rate influence measure generated by the candidate selection model (CSM). The estimated rate of features weights that are ruled to create the activation function is called the intra-class activation function. Further, the activation fixes the logical rules to make predictions fed to the feature weights into the neural classifier. The RNN predicts the results which are trained based on logical rules iterated in the neural classifier. The classifier makes successive predictions that are grown up to make the right recommendation of compound molecules to reduce the risk of the side effects. The proposed SDFC-CAM with InS2ARNN classification algorithm aims to provide efficient drug recommendations. The proposed algorithm achieves 94% of prediction results for drug recommendations compared to the existing algorithms.

El texto completo de este artículo está disponible en PDF.

Keywords : Drug analysis, Healthcare data analysis, feature selection, Recurrent Neural Network, CSM, prediction and classification


Esquema


© 2022  The Author(s). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.